Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy - Concepedia

Concepedia

Publication | Open Access

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

DOI Full Paper Access

71

Citations

12

References

2009

Year

Jørn Herrstedt, Wichit Apornwirat, Ahmed Shaharyar, Zeba Aziz, Fausto Roila, Simon Van Belle, Mark W. Russo, Jeremey Levin, Mary Guckert, Steven M. Grunberg

Journal of Clinical Oncology

Abstract

All casopitant regimens studied were more effective than the control regimen. Casopitant was generally well tolerated.

References

	Year	Citations

Page 1